Supplement 3

Figure A. Drug-susceptible tuberculosis patient series vs drug-susceptible tuberculosis population-based studies for % of predicted FEV1



Figure B. Drug-susceptible tuberculosis patient series vs drug-susceptible tuberculosis population-based studies for % of predicted FVC



Figure C. Drug-susceptible tuberculosis patient series vs drug-susceptible tuberculosis population-based studies for obstructive type of lung impairment



Figure D. Drug-susceptible tuberculosis patient series vs drug-susceptible tuberculosis population-based studies for mixed type of lung impairment

Author	Year	Country	Age	% male	% smokers	Selection	N	Proportion of Mixed Pattern on Spirometry	95% CI
Patient series									
Fiogbe	2018	Benin	37	68	20	Patient series	189	0.03	[0.01; 0.06]
Mbatchou Ngahane	2016	Cameroon	33	54	10	Patient series	269	0.05	[0.03; 0.09]
Bemba	2017	Congo	34	61	21	Patient series	150	0.11	[0.07; 0.17]
Meghji	2020	Malawi	35	68	30	Patient series	405		
Khosa	2020	Mozambique	29	68	35	Patient series	62	0.13	[0.07; 0.23]
Ojuawo	2020	Nigeria	39	56	.	Patient series	308	0.24	[0.20; 0.29]
Willcox	1989	South Africa	50	66	.	Patient series	71	0.20	[0.12; 0.30]
Plit	1998	South Africa	35	70	58	Patient series	74		
Daniels	2019	South Africa	39	56	78	Patient series	45	0.02	[0.00; 0.12]
Stek	2019	South Africa	38	59	50	Patient series	111		
Osman	2016	Sudan	44	73	.	Patient series	136		
Manji	2016	Tanzania	35	60	29	Patient series	501	0.19	[0.16; 0.23]
Jones	2017	Uganda	45	48	34	Patient series	29		
Ramos	2005	Brazil	30	40	46	Patient series	50	0.34	[0.22; 0.48]
Di Naso (DS)	2011	Brazil	32	80	60	Patient series	15	0.27	[0.11; 0.52]
Mancuzo	2019	Brazil	40	52	39	Patient series	378	0.18	[0.14; 0.22]
Báez-Saldaña	2013	Mexico	48	43	0	Patient series	127		
Snider	1971	USA	44	68	84	Patient series	1403	0.19	[0.17; 0.21]
Pasipanodya	2007	USA	47	69	57	Patient series	107	0.13	[0.08; 0.21]
Pasipanodya	2012	USA	47	70	55	Patient series	317	0.16	[0.12; 0.21]
Chushkin	2017	Russia	51	62	64	Patient series	214	0.04	[0.02; 0.07]
Banu Rekha	2009	India	.	66	33	Patient series	148	0.16	[0.11; 0.23]
Akkara	2013	India	35	74	0	Patient series	257		
Dhipu Mathew	2016	India	54	68	.	Patient series	75	0.19	[0.11; 0.29]
Gandhi	2016	India	34	66	28	Patient series	146	0.13	[0.08; 0.19]
Santra	2017	India	53	84	44	Patient series	138	0.72	[0.64; 0.79]
Gupte	2019	India	32	52	20	Patient series	172		
Patil	2020	India	45	60	0	Patient series	1000	0.16	[0.14; 0.18]
Baig	2010	Pakistan	53	76	0	Patient series	47	0.15	[0.07; 0.28]
Rhee	2013	South Korea	65	60	43	Patient series	595		
Chung	2011	Taiwan	59	76	48	Patient series	106	0.09	[0.05; 0.17]
Random effects model							7645	0.15	[0.10; 0.20]
Heterogeneity: I^2 = 93%, p < 0.01									
Population-based									
Nihues Sde	2015	Brazil	40	52	52	Population-based	100	0.19	[0.13; 0.28]
Menezes	2007	multiple*	56	39	57	Population-based	132		
Powers	2019	USA	60	44	71	Population-based	344		
Mattila	2016	Finland	.	56	52	Population-based	1191		
Lam	2010	China	64	39	32	Population-based	2186		
Lee	2011	South Korea	53	63	53	Population-based	294		
Hwang	2014	South Korea	51	64	37	Population-based	167		
Kim	2019	South Korea	57	60	56	Population-based	1482		
Random effects model							**13541**	**0.15**	**[0.11; 0.20]**

Heterogeneity: I^2 = 92%, p < 0.01
Test for subgroup differences: χ^2_1 = 0.97, df = 1 (p = 0.32)



Figure E. Drug-susceptible tuberculosis patient series vs drug-susceptible tuberculosis population-based studies for restrictive type of lung impairment